secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2026-10-15T20:10:52+00:00
Accession:  0001356576-26-000040
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.07, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Supernus stockholders approve merger with Indivior; 48.25M votes for, 235,601 against
--------------------------------------------------------------------------------

- Proposal 1 (adoption of Merger Agreement) passed: 48,249,532 votes for, 235,601 against, 67,004 abstained, no broker non-votes.
- Under the deal, Artemis Merger Sub, Inc. merges into Supernus, which survives as a wholly-owned subsidiary of Indivior Pharmaceuticals Inc.
- Proposal 2 (non-binding golden-parachute compensation for named executive officers) passed 32,688,410 for vs 15,847,350 against, 16,377 abstained.
- Special Meeting held October 15, 2026; 58,224,143 shares outstanding and entitled to vote as of the September 4, 2026 record date.
- Proxy statement for the Special Meeting was filed with the SEC on September 11, 2026; merger closing conditions not detailed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000040/0001356576-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000040/supn-20261015.htm
  HTML page:      https://secwatch.observer/filing/0001356576-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer